Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19865634 | 0.85 | LRRK2 (0.48) | LRRK2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL26160279 | 0.79 | LRRK2 (0.43) | LRRK2 | |
| SCHEMBL19862554 | 0.78 | TAS1R3 (0.44) | LMNA | |
| SCHEMBL14072565 | 0.77 | LRRK2 (0.46) | LRRK2 | |
| SCHEMBL24995730 | 0.76 | PDPK1 (0.53) | LRRK2 | |
| SCHEMBL18435285 | 0.75 | TAS1R3 (0.52) | ALDH1A1 | |
| SCHEMBL16252290 | 0.75 | TAS1R3 (0.52) | ALDH1A1 | |
| SCHEMBL4138513 | 0.74 | LRRK2 (0.43) | LRRK2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4517438 | 0.74 | PGR (0.58) | LRRK2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4526621 | 0.74 | CYP11B2 (0.49) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | LRRK2 2484/4885ALDH1A1 436/4885LMNA 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.